SlateStone Wealth LLC Increases Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

SlateStone Wealth LLC raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 4.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 10,640 shares of the company’s stock after buying an additional 413 shares during the quarter. SlateStone Wealth LLC’s holdings in Hims & Hers Health were worth $257,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. State Street Corp raised its stake in Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the last quarter. Geode Capital Management LLC raised its stake in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Hims & Hers Health by 7.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock valued at $43,448,000 after acquiring an additional 129,416 shares during the period. Finally, Yong Rong HK Asset Management Ltd bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at $41,104,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 5.0 %

HIMS opened at $33.10 on Monday. The firm has a 50-day simple moving average of $38.49 and a two-hundred day simple moving average of $28.23. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The company has a market capitalization of $7.35 billion, a PE ratio of 75.24 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In related news, insider Michael Chi sold 7,500 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $26.00, for a total value of $195,000.00. Following the sale, the insider now directly owns 193,601 shares of the company’s stock, valued at $5,033,626. This represents a 3.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 890,592 shares of company stock worth $31,677,291. 17.71% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Bank of America reissued an “underperform” rating and set a $21.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Leerink Partners boosted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Piper Sandler boosted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, February 25th. Finally, BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus price target of $37.23.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.